FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to medicine and pharmaceutics, namely to a vaginal suppository for treating infectious-inflammatory diseases of the vulva and vagina, particularly vulvar and vaginal diseases caused by Candida fungi, for example, vaginal and vulvovaginal candidiasis, where said vaginal suppository containing an active ingredient – sodium tetraborate, dispersed in the base – fat, which is solid at room temperature, which is a mixture of triglycerides, diglycerides and medium-chain (C16-C18) monoglycerides of fatty acids with hydroxyl number of 40 to 50 mg KOH/g, as well as an emulsifier – polyoxyethylene (20) sorbitan monooleate and an additive preventing melting temperature reduction and time of complete suppository deformation – distilled monoglycerides, and to a method of such suppository manufacturing.
EFFECT: providing a convenient, safe in use and storage stable dosage form of sodium tetraborate providing in its medical application uniform distribution of the drug on the vaginal mucosa.
13 cl, 5 ex, 4 tbl, 1 dwg
Title | Year | Author | Number |
---|---|---|---|
ANTIBACTERIAL SUPPOSITORIES | 2014 |
|
RU2578454C1 |
ANTIBACTERIAL SUPPOSITORIES | 2015 |
|
RU2595852C1 |
SUPPOSITORIES WITH SODIUM AMINODIHYDROPHTHALAZINEDIONE | 2020 |
|
RU2760262C1 |
PHARMACOLOGICAL COMPOSITION FOR TREATMENT OF CANDIDOSE VULVAVAGINATES | 2007 |
|
RU2354385C2 |
ANTIBACTERIAL AGENT | 2006 |
|
RU2318523C2 |
METHOD OF TREATING UROGENITAL CANDIDIASIS USING ULTRASONIC CAVITATION AND PHOTOCHROMOTHERAPY | 2019 |
|
RU2704470C1 |
VAGINAL SUPPOSITORY ELICITING WITH CONTRACEPTIVE EFFECT | 2004 |
|
RU2257197C1 |
METHOD FOR TREATMENT OF VAGINAL CANDIDOSIS | 2004 |
|
RU2254857C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING UROGENITAL INFECTIONS | 2008 |
|
RU2401102C2 |
SUPPOSITORY EXHIBITING ANTIFUNGAL EFFECT (VARIANTS) | 1996 |
|
RU2139707C1 |
Authors
Dates
2019-07-30—Published
2019-01-24—Filed